remogliflozin etabonate + furosemide

This is a **combination drug** that includes **remogliflozin etabonate**, a prodrug SGLT2 inhibitor developed for type 2 diabetes mellitus, and **furosemide**, a loop diuretic commonly used for treating fluid overload and hypertension. Remogliflozin etabonate works by selectively inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, increasing urinary glucose excretion, improving glycemic control, and offering modest weight loss and blood pressure reduction. Furosemide acts on the loop of Henle in the kidneys to block sodium and chloride reabsorption, resulting in increased urine output and excretion of electrolytes. The combination was evaluated for safety, tolerability, and effects on serum electrolytes and fluid balance in diabetes patients. Combined administration increases urinary glucose excretion, osmolality, and osmolar clearance, with potential safety concerns including modest volume depletion[1].